- Home
- INSM vs USFD Comparison
INSM vs USFD Comparison
Compare INSM & USFD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSM
- USFD
- Stock Information
- Founded
- INSM 1988
- USFD 2007
- Country
- INSM United States
- USFD United States
- Employees
- INSM N/A
- USFD N/A
- Industry
- INSM Biotechnology: Pharmaceutical Preparations
- USFD Food Distributors
- Sector
- INSM Health Care
- USFD Consumer Discretionary
- Exchange
- INSM Nasdaq
- USFD Nasdaq
- Market Cap
- INSM 12.5B
- USFD 13.0B
- IPO Year
- INSM 2000
- USFD 2016
- Fundamental
- Price
- INSM $72.27
- USFD $61.25
- Analyst Decision
- INSM Strong Buy
- USFD Strong Buy
- Analyst Count
- INSM 16
- USFD 13
- Target Price
- INSM $82.00
- USFD $65.38
- AVG Volume (30 Days)
- INSM 1.8M
- USFD 2.1M
- Earning Date
- INSM 10-24-2024
- USFD 11-07-2024
- Dividend Yield
- INSM N/A
- USFD N/A
- EPS Growth
- INSM N/A
- USFD 12.12
- EPS
- INSM N/A
- USFD 2.10
- Revenue
- INSM $328,605,000.00
- USFD $36,700,000,000.00
- Revenue This Year
- INSM $19.10
- USFD $8.44
- Revenue Next Year
- INSM $44.67
- USFD $4.99
- P/E Ratio
- INSM N/A
- USFD $29.04
- Revenue Growth
- INSM 21.94
- USFD 4.90
- 52 Week Low
- INSM $21.92
- USFD $35.66
- 52 Week High
- INSM $80.53
- USFD $62.94
- Technical
- Relative Strength Index (RSI)
- INSM 46.30
- USFD 57.69
- Support Level
- INSM $71.11
- USFD $60.69
- Resistance Level
- INSM $73.81
- USFD $61.70
- Average True Range (ATR)
- INSM 2.15
- USFD 1.07
- MACD
- INSM -0.10
- USFD -0.22
- Stochastic Oscillator
- INSM 36.26
- USFD 56.98
About INSM Insmed Incorporated
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.
About USFD US Foods Holding Corp.
US Foods Holding Corp is the U.S. food service distributor. us Foods distributes food and nonfood products to the healthcare and hospitality industries, restaurants, and education, government facilities, and grocers. In addition to its delivery business, the firm has 80 cash-and- carry stores under the Chef'Store banner. The company generates majority of the revenue from Meats and seafood products.